Evidence map›Paper›PMID 39689176›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

The impact of treatment strategies on the epidemiological dynamics of plasmid-conferred antibiotic resistance.

Malte Muetter, Daniel C Angst, Roland R Regoes, Sebastian Bonhoeffer

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Malte MuetterInstitute of Integrative Biology, Department for Environmental System Science, ETH Zurich, Zurich 8092, Switzerland.ORCID 0009-0005-9262-7306
Daniel C AngstInstitute of Integrative Biology, Department for Environmental System Science, ETH Zurich, Zurich 8092, Switzerland.ORCID 0000-0002-6512-4595
Roland R RegoesInstitute of Integrative Biology, Department for Environmental System Science, ETH Zurich, Zurich 8092, Switzerland.ORCID 0000-0001-8319-5293
Sebastian BonhoefferInstitute of Integrative Biology, Department for Environmental System Science, ETH Zurich, Zurich 8092, Switzerland.ORCID 0000-0001-8052-3925

Funding

Non-US Government Research Support type
6 · The paper itself

Abstract

The issue of antibiotic resistance is a critical concern for public health, prompting numerous investigations into the impact of treatment strategies on preventing or slowing down the emergence of resistance. While existing studies have predominantly focused on chromosomal resistance mutations, the consequences of often clinically more relevant plasmid-conferred resistance remain insufficiently explored. To address this gap, we conducted three extensive in vitro experiments utilizing a liquid-handling platform. These experiments evaluated the efficacy of five distinct treatment strategies using two antibiotics (tetracycline and ceftazidime) along with two horizontally transmissible clinical resistance plasmids conferring the respective resistances. Among the experimentally investigated treatment strategies, combination therapy proved to be the most effective in preventing the emergence of double resistance while minimizing the number of infections. To verify the reliability of these findings, we constructed a computational model of our experiments that we parameterized using the experimental data. We employed this model to augment the experimental data by conducting an in silico parameter sensitivity analysis. The sensitivity analysis corroborated our experimental results, demonstrating that combination therapy consistently outperformed other treatment strategies across a range of parameter values.

Indexed as

Anti-Bacterial AgentsPlasmidsCeftazidimeComputer SimulationDrug Resistance, BacterialDrug Resistance, MicrobialDrug Resistance, Multiple, BacterialEscherichia coliHumansMicrobial Sensitivity TestsTetracyclineAnti-Bacterial AgentsCeftazidimeTetracyclineantibiotic resistancecombination therapyexperimental epidemiologyplasmidstreatment strategies

Identifiers

PMID39689176
PMCPMC11670247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.